# British Journal of Dermatology

**Type:** Journals  
**Canonical URL:** https://scholariq.org/journals/british-journal-of-dermatology/

## Facts

| Field | Value |
| --- | --- |
| APC (USD) | 4,600 |
| Citations | 1,013,577 |
| h-index | 263 |
| Homepage | https://academic.oup.com/bjd |
| Open Access | false |
| ISSN-L | 0007-0963 |
| ISSNs | 0007-0963,1365-2133 |
| OpenAlex ID | https://openalex.org/S45720283 |
| Publisher | Oxford University Press |
| Works | 42,641 |

## Journal papers

Showing 12 of 138.

- [The U.K. Working Party's Diagnostic Criteria for Atopic Dermatitis..](https://scholariq.org/papers/the-u-k-working-party-s-diagnostic-criteria-for-atopic-dermatitis/)
- [Classification of the cutaneous manifestations of <scp>COVID</scp> ‐19: a rapid prospective nationwide consensus study in Spain with 375 cases](https://scholariq.org/papers/classification-of-the-cutaneous-manifestations-of-scp-covid-scp-19-a-rapid/)
- [Drug reaction with eosinophilia and systemic symptoms (DRESS): an original multisystem adverse drug reaction. Results from the prospective RegiSCAR study](https://scholariq.org/papers/drug-reaction-with-eosinophilia-and-systemic-symptoms-dress-an-original/)
- [Consensus reclassification of inherited epidermolysis bullosa and other disorders with skin fragility](https://scholariq.org/papers/consensus-reclassification-of-inherited-epidermolysis-bullosa-and-other/)
- [Prevalence of metabolic syndrome in patients with psoriasis: a hospital-based case?control study](https://scholariq.org/papers/prevalence-of-metabolic-syndrome-in-patients-with-psoriasis-a-hospital-based/)
- [Tralokinumab for moderate‐to‐severe atopic dermatitis: results from two 52‐week, randomized, double‐blind, multicentre, placebo‐controlled phase III trials (ECZTRA 1 and ECZTRA 2)*](https://scholariq.org/papers/tralokinumab-for-moderate-to-severe-atopic-dermatitis-results-from-two-52-week/)
- [Epidemiology and comorbidity of psoriasis in children](https://scholariq.org/papers/epidemiology-and-comorbidity-of-psoriasis-in-children/)
- [Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate‐to‐severe plaque psoriasis over 52 weeks: a phase III, randomized controlled trial (ESTEEM 2)](https://scholariq.org/papers/efficacy-and-safety-of-apremilast-an-oral-phosphodiesterase-4-inhibitor-in/)
- [Dupilumab with concomitant topical corticosteroid treatment in adults with atopic dermatitis with an inadequate response or intolerance to ciclosporin A or when this treatment is medically inadvisable: a placebo-controlled, randomized phase III clinical t](https://scholariq.org/papers/dupilumab-with-concomitant-topical-corticosteroid-treatment-in-adults-with/)
- [Development and validation of the International Hidradenitis Suppurativa Severity Score System ( <scp>IHS</scp> 4), a novel dynamic scoring system to assess <scp>HS</scp> severity](https://scholariq.org/papers/development-and-validation-of-the-international-hidradenitis-suppurativa/)
- [Conjunctivitis in dupilumab clinical trials](https://scholariq.org/papers/conjunctivitis-in-dupilumab-clinical-trials/)
- [Topical tofacitinib for atopic dermatitis: a phase <scp>II</scp> a randomized trial](https://scholariq.org/papers/topical-tofacitinib-for-atopic-dermatitis-a-phase-scp-ii-scp-a-randomized-trial/)

## Journal top topics

Showing 8 of 24.

- [Autoimmune Bullous Skin Diseases](https://scholariq.org/topics/autoimmune-bullous-skin-diseases/)
- [Dermatology and Skin Diseases](https://scholariq.org/topics/dermatology-and-skin-diseases/)
- [Psoriasis: Treatment and Pathogenesis](https://scholariq.org/topics/psoriasis-treatment-and-pathogenesis/)
- [Cutaneous Melanoma Detection and Management](https://scholariq.org/topics/cutaneous-melanoma-detection-and-management/)
- [Cutaneous lymphoproliferative disorders research](https://scholariq.org/topics/cutaneous-lymphoproliferative-disorders-research/)
- [Nail Diseases and Treatments](https://scholariq.org/topics/nail-diseases-and-treatments/)
- [Skin and Cellular Biology Research](https://scholariq.org/topics/skin-and-cellular-biology-research/)
- [Nonmelanoma Skin Cancer Studies](https://scholariq.org/topics/nonmelanoma-skin-cancer-studies/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.